Gasdermin E links tumor cell-intrinsic nucleic acid signaling to proinflammatory cell death for successful checkpoint inhibitor cancer immunotherapy [0.03%]
Gasdermin E连接肿瘤细胞内在核苷酸信号至促炎性细胞死亡以实现成功的免疫检查点抑制剂癌症免疫治疗
Stefan Enssle,Anna Sax,Peter May et al.
Stefan Enssle et al.
Durable clinical responses to immune checkpoint inhibitors (ICI) are limited to a minority of patients, and molecular pathways that modulate their efficacy remain incompletely defined. We have recently shown that activation of the innate RN...
CD8+ T cells in breast cancer tumors and draining lymph nodes: PD-1 levels, effector functions and prognostic relevance [0.03%]
乳腺肿瘤和引流淋巴结中CD8+t细胞：PD-1水平、效应功能及预后意义
Carolina Abrate,Fernando P Canale,Sabrina N Bossio et al.
Carolina Abrate et al.
CD8+ T cells shape the antitumor immune response. Here, we evaluated CD8+ T cells expressing different levels of PD-1, their functional status, and distribution in different tissues of luminal breast cancer (BC) patients. We characterized t...
Avelumab induces greater Fc-Fc receptor-dependent natural killer cell activation and dendritic cell crosstalk compared to durvalumab [0.03%]
与德瓦卢单抗相比，阿维鲁单抗能诱导更强的Fc-Fc受体依赖性的自然杀伤细胞活化和树突状细胞相互作用
Nicole Osborne,Amit Rupani,Vladimir Makarov et al.
Nicole Osborne et al.
Several FDA-approved anti-PD-L1 (programmed cell death ligand-1) monoclonal antibodies (mAbs) are used to treat cancer. While these mAbs primarily target and intercept PD-L1:PD-1 inhibitory signaling in T-cells, the Fc-domains of these mAbs...
TNFR2/CCR8 bispecific antibody enhances antitumor activity through depleting Ti-Tregs and boosting effector CD8+ T cell function [0.03%]
靶向TNFR2/CCR8的双特异性抗体通过耗竭Ti-Tregs和促进效应CD8+t细胞功能增强抗肿瘤活性
Ran Wang,Jiefang Xu,Shipeng Cheng et al.
Ran Wang et al.
Modulation or depletion of tumor-infiltrating Tregs (Ti-Tregs) is a promising strategy in the field of antitumor immunotherapy. However, this approach poses challenges due to the diversity within the Treg population and the lack of precisio...
Glutamate promotes CCL2 expression to recruit tumor-associated macrophages by restraining EZH2-mediated histone methylation in hepatocellular carcinoma [0.03%]
谷氨酸通过限制EZH2介导的组蛋白甲基化促进肝细胞癌中CCL2表达以募集肿瘤相关巨噬细胞
Jing Chen,Hong-Wei Sun,Run-Zheng Wang et al.
Jing Chen et al.
Glutamate is well-known as metabolite for maintaining the energy and redox homeostasis in cancer, moreover it is also the primary excitatory neurotransmitter in the central nervous system. However, whether glutamatergic signaling can regula...
Impact of steroid dose and timing on efficacy of combination PD-1/CTLA-4 blockade [0.03%]
糖皮质激素剂量和时机对PD-1/CTLA-4联合阻断疗效的影响
Nina B Curkovic,Rebecca Irlmeier,Xue Bai et al.
Nina B Curkovic et al.
With the increasing use of immune checkpoint inhibitors (ICIs) in combination regimens and in earlier stages of advanced melanoma, the effective management of immune-related adverse events (irAEs) is key to balancing immunotherapy efficacy ...
Multicenter Study
Oncoimmunology. 2025 Dec;14(1):2494433. DOI:10.1080/2162402X.2025.2494433 2025
Targeting the atypical chemokine receptor 2 (Ackr2) improves the benefit of anti-PD-1 immunotherapy in melanoma mouse model [0.03%]
靶向非典型趋化因子受体2（Ackr2）可增强小鼠黑色素瘤模型中抗PD-1免疫疗法的疗效
Muhammad Zaeem Noman,Martyna Szpakowska,Malina Xiao et al.
Muhammad Zaeem Noman et al.
Immune checkpoint blockade (ICB) therapies, such as anti-PD-1, have transformed cancer treatment, but many patients do not respond due to a non-inflammatory tumor microenvironment (TME). Here, we investigated the impact of targeting Atypica...
Final 3-year results from the EVIDENS study, an observational study of nivolumab in non-small cell lung cancer [0.03%]
EVIDENS研究的最终3年结果：一项关于纳武利尤单抗治疗非小细胞肺癌的观察性研究
Fabrice Barlesi,Adrien Dixmier,Didier Debieuvre et al.
Fabrice Barlesi et al.
EVIDENS was a prospective, non-interventional, longitudinal study conducted in non-small cell lung cancer (NSCLC) patients receiving nivolumab in France. It recruited adults with pathologically confirmed NSCLC who initiated nivolumab betwee...
Observational Study
Oncoimmunology. 2025 Dec;14(1):2492932. DOI:10.1080/2162402X.2025.2492932 2025
Smad7 is a negative regulator of immunogenic cell death in colorectal cancer [0.03%]
SMAD7是结直肠癌免疫原性细胞死亡的负调节因子
Claudia Maresca,Eleonora Franzè,Federica Laudisi et al.
Claudia Maresca et al.
Induction of endoplasmic reticulum (ER) stress is followed by exposure of calreticulin (CRT) on the cancer cell plasma membrane and elicits an anticancer immune response, referred to as immunogenic cell death (ICD). Smad7 is highly expresse...
Novel immunodominant neoepitope in a KPC mouse model of pancreatic cancer allowing identification of tumor-specific T cells [0.03%]
一种新型免疫优势neoepitope的胰腺癌小鼠模型(KPC)能够识别特异性肿瘤T细胞
Maria Antsiferova,Marco Berrera,Anne-Claire Zagdoun et al.
Maria Antsiferova et al.
The 4662 KPC model is one of the most widely used mouse models of pancreatic cancer. It represents an excluded immune phenotype and closely recapitulates the pathophysiology of pancreatic cancer in humans. We set out to identify the endogen...